

What is claimed is:

1. A antibody which, when bound to human iRhom2, binds at least within a region of human iRhom2 spanning from and including S474 to and including S660 of SEQ ID NO: 181.
2. The antibody according to claim 1, which binds within at least a region of human iRhom2 spanning from and including W526 to and including I566 of SEQ ID NO: 181.
3. The antibody according to claim 1 or 2, which binds a stretch of human iRhom2 comprising at least one residue selected from the group comprising W526; Q527; P532; P533; M534; D535; K536; S537; L539; K542; R543; T544; G546; R554; E557; S561; S562 and/or I566 of SEQ ID NO: 181.
4. The antibody according to any one of claims 1 - 3, which inhibits and/or reduces TACE/ADAM17 activity when bound to human iRhom2.
5. The antibody according to claim 4, wherein the inhibition or reduction of TACE/ADAM17 activity is caused by interference with iRhom2-mediated TACE/ADAM17 activation.
6. The antibody according to any one of claims 1 – 5, which, when bound to human iRhom2,
 - inhibits or reduces induced TNF α shedding,
 - inhibits or reduces induced IL-6R shedding, and/or
 - inhibits or reduces induced HB-EGF shedding.
7. The antibody according to any one of claims 1 - 6, which is a monoclonal antibody, or a target-binding fragment thereof, or an antibody in at least one of the formats selected from the group consisting of: IgG, scFv, Fab, or (Fab)₂.

8. The antibody according to any one of claims 1 - 7, which is not cross-reactive with human iRhom1.

9. The antibody according to any one of claims 7 - 8, which

a) comprises a set of heavy chain/light chain complementarity determining regions (CDR) comprised in the heavy chain/light variable domain sequence pair set forth in the following pairs of SEQ ID NOs:

2 and 7; 12 and 17; 22 and 27; 32 and 37; 42 and 47; 52 and 57; 62 and 67; 72 and 77; 82 and 87; 112 and 117; 152 and 157; 162 and 167; or 172 and 177;

b) comprises a set of heavy chain/light chain complementarity determining regions (CDR) comprising the following SEQ ID NOs, in the order HCDR1; HCDR2; HCDR3; LCDR1; LCDR2 and LCDR3

- 3, 4, 5, 8, 9, 10;
- 13, 14, 15, 18, 19, 20;
- 23, 24, 25, 28, 29, 30;
- 33, 34, 35, 38, 39, 40;
- 43, 44, 45, 48, 49, 50;
- 53, 54, 55, 58, 59, 60;
- 63, 64, 65, 68, 69, 70;
- 73, 74, 75, 78, 79, 80;
- 83, 84, 85, 88, 89, 90;
- 113, 114, 115, 118, 119, 120;
- 153, 154, 155, 158, 159, 160;
- 163, 164, 165, 168, 169, 170; or
- 173, 174, 175, 178, 179, 180;

wherein the CDRs are embedded in a human VH/VL framework so as to be capable to bind to human iRhom2 with a K_D of 10^{-4} or smaller and to inhibit or reduce TACE/ADAM17 activity.

10. The antibody according to any one of claims 7 - 9, which comprises

the heavy chain/light chain variable domain (HCVD/LCVD) pairs set forth in the following pairs of SEQ ID NOs:

2 and 7; 12 and 17; 22 and 27; 32 and 37; 42 and 47; 52 and 57; 62 and 67; 72 and 77; 82 and 87; 112 and 117; 152 and 157; 162 and 167; or 172 and 177.
11. A nucleic acid that encodes for an antibody according to any one of claims 1 - 10.
12. A pharmaceutical composition comprising the antibody according to any one of claims 1 – 10 or the nucleic acid according to claim 11, and optionally one or more pharmaceutically acceptable excipients.
13. A combination comprising (i) the antibody according to any one of claims 1 – 10, the nucleic acid according to claim 11, or the pharmaceutical composition according to claim 12 and (ii) one or more therapeutically active compounds.
14. Use of the antibody according to any one of claims 1 – 10, the nucleic acid according to claim 11, the pharmaceutical composition according to claim 12, or the combination according to claim 13, for the manufacture of a medicament in the treatment of a human or animal subject
 - being diagnosed for,
 - suffering from or
 - being at risk of developingan inflammatory condition, or for the prevention of such condition, wherein the inflammatory condition is Rheumatoid Arthritis (RA).

15. A therapeutic kit of parts comprising:

- a) the antibody according to any one of claims 1 – 10, the nucleic acid according to claim 11, the pharmaceutical composition according to claim 12 or the combination according to claim 13,
- b) an apparatus for administering the antibody, the nucleic acid, the pharmaceutical composition or the combination, and
- c) instructions for use.